Modified NK-92 haNK003 cells for the clinic
Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.
1. A population of modified NK-92 cells having antibody-dependent cell-mediated cytotoxicity (ADCC) comprising a polypeptide sequence with at least 90% identity to CD16 (SEQ ID NO:4) and a polypeptide sequence with at least 90% identity to IL-2 (SEQ ID NO:6), wherein greater than 90% of the cells in the population of cells express CD56, CD16, CD54, and NKp30 and less than 5% of the cells in the population of cells express CD3 and wherein the cells further comprise SEQ ID NO:1 on chromosome 17.
2. The cells of claim 1 , wherein the mean doubling time of the cells is between 55 and 70 hours.
3. The cells of claim 1 , wherein the population of cells maintains the mean doubling time from 1, 2, 3, 4, 5, 10, 15, 20, or 25 days.
4. The cells of claim 1 , wherein the population of cells can be passaged every 1, 2, 3, or 4 days.
5. The cells of claim 1 , wherein the cells secrete IL-2 at a concentration of 10 to 60 pg/hour per million cells.
6. The cells of claim 1 , wherein the cells are irradiated cells.
7. The cells of claim 1 , wherein the cells have reduced downregulation of expression of CD16 compared to a control.
8. The cells of claim 1 , wherein the cells maintain higher levels of CD16 after ADCC compared to a control.
9. A kit comprising the population of cells of claim 1 .
10. The kit of claim 9 , further comprising an antibody.
11. A pharmaceutical composition comprising the population of cells of claim 1 and a pharmaceutically acceptable excipient.